Back to top

Analyst Raises Ligand Price Target to $388 on XOMA-Driven Growth Outlook and Enhanced Royalty Portfolio

Jason Zemansky, an analyst from Bank of America Securities, reiterated the Buy rating on Ligand Pharma. The associated price target was raised to $...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ligand Pharmaceuticals Incorporated (LGND)